Eli Lilly and Company $LLY Stock Position Lifted by Bank Julius Baer & Co. Ltd Zurich

Key Points

• Bank Julius Baer modestly increased its Eli Lilly position by 844 shares in the third quarter, bringing its holdings to 914,092 shares valued at approximately $1.06 billion. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, beating consensus estimates. Robust demand for Mounjaro and Zepbound prompted the company to raise its full-year outlook.
• Analyst sentiment remains positive, with several firms raising price targets and MarketBeat reporting an overall “Moderate Buy” rating with an average target of $1,404.14. However, investors face risks from Lilly’s premium valuation, heavy reliance on GLP-1 drugs, and potential pricing pressure.

Bank Julius Baer & Co. Ltd Zurich grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 914,092 shares of the company's stock after purchasing an additional 844 shares during the quarter. Eli Lilly and Company accounts for about 2.7% of Bank Julius Baer & Co. Ltd Zurich's holdings, making the stock its 8th biggest holding. Bank Julius Baer & Co. Ltd Zurich owned about 0.10% of Eli Lilly and Company worth $1,061,854,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Virtue Capital Management LLC lifted its position in shares of Eli Lilly and Company by 40.3% during the 3rd quarter. Virtue Capital Management LLC now owns 926 shares of the company's stock worth $1,072,000 after purchasing an additional 266 shares during the last quarter. Heritage Investors Management Corp grew its stake in shares of Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company's stock worth $13,624,000 after purchasing an additional 718 shares in the last quarter. Austin Asset Management Co Inc increased its holdings in Eli Lilly and Company by 3.3% in the third quarter. Austin Asset Management Co Inc now owns 3,253 shares of the company's stock valued at $3,764,000 after buying an additional 103 shares during the last quarter. Verus Financial Partners Inc. raised its stake in Eli Lilly and Company by 4.8% in the third quarter. Verus Financial Partners Inc. now owns 330 shares of the company's stock valued at $381,000 after buying an additional 15 shares in the last quarter. Finally, Columbia Bank raised its stake in Eli Lilly and Company by 2.2% in the third quarter. Columbia Bank now owns 3,674 shares of the company's stock valued at $4,251,000 after buying an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research report on Monday. Leerink Partners raised their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 21st. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an "overweight" rating in a research note on Friday. UBS Group boosted their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a "buy" rating in a research note on Friday. Finally, TD Cowen reaffirmed a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,404.14.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,412.06 on Tuesday. The stock's 50-day moving average is $1,200.81 and its two-hundred day moving average is $1,094.25. The firm has a market cap of $1.33 trillion, a price-to-earnings ratio of 40.91, a PEG ratio of 1.73 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,449.68. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the previous year, the firm earned $7.02 earnings per share. The business's revenue was up 38.6% compared to the same quarter last year. Analysts predict that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.